Novel Peripherally Selective Cannabinoid Receptor 1 Neutral Antagonist Improves Metabolic Dysfunction-Associated Steatotic Liver Disease in Mice-Reference-Cited by-同舟云学术

Novel Peripherally Selective Cannabinoid Receptor 1 Neutral Antagonist Improves Metabolic Dysfunction-Associated Steatotic Liver Disease in Mice

Published:2024-08-08 Issue:9 Volume:7 Page:2856-2868
ISSN:2575-9108
Container-title:ACS Pharmacology & Translational Science
language:en
Short-container-title:ACS Pharmacol. Transl. Sci.

Author:

Laudermilk Lucas T.¹,Schlosburg Joel E.²,Gay Elaine A.¹,Decker Ann M.¹^ORCID,Williams Aaron³,Runton Rubica⁴^ORCID,Vasukuttan Vineetha¹,Kotiya Archana¹,Amato George S.¹,Maitra Rangan¹⁵^ORCID

Affiliation:

1. Center for Drug Discovery, RTI International, Research Triangle Park, North Carolina 27709-2194, United States

2. Department of Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, Virginia 23298-0565, United States

3. Undergraduate Studies, Clemson University, Clemson, South Carolina 29634, United States

4. Undergraduate Studies, Georgia Institute of Technology, Atlanta, Georgia 30332-0002, United States

5. Artiam Bio Inc., Cary, North Carolina 27513-2754, United States

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

National Institute on Drug Abuse

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acsptsci.4c00356

Reference83 articles.

1. Management of NAFLD: a stage-based approach

2. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

3. Epidemiology of non-alcoholic and alcoholic fatty liver diseases

4. Metabolic Targets in Nonalcoholic Fatty Liver Disease

5. Caloric restriction lowers endocannabinoid tonus and improves cardiac function in type 2 diabetes